SIR 2024
Interventional Oncology
David Chlorogiannis, MD
Research Scholar
Brigham and Women's Hospital, Harvard Medical School
Financial relationships: Full list of relationships is listed on the CME information page.
Zisis Kratiras, MD
Assistant Professor
Department of Urology, University Hospital of Athens "Attikon", Greece
Disclosure information not submitted.
Nikolaos Kelekis, MD, PhD
Professor of Radiology and Interventional Radiology
University General Hospital 'ATTIKON', Greece
Disclosure information not submitted.
Evgenia Efthymiou, MD
Radiology Consultant
2nd Department of Radiology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Napoleon Moulavasilis, MD
Consultant
1st Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Michail Chrisofos, MD
Consultant
Department of Urology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Konstantinos Stravodimos, MD
Consultant
1st Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Dimitrios Filippiadis, MD, PhD, MS (he/him/his)
Associate Professor in Interventional Radiology
University General Hospital "ATTIKON", Greece
Financial relationships: Full list of relationships is listed on the CME information page.
There has been a noteworthy increase in the incidence of Stage I renal cell carcinoma (RCC) in recent years, primarily due to incidental detection on cross-sectional imaging. Percutaneous Microwave Ablation (MWA) has demonstrated comparable short-term efficacy and a favorable safety profile in comparison to the standard of care Partial Nephrectomy (PN). However, there is a dearth of literature comparing its long term outcomes.
Materials and Methods:
This single-center, institutional review board–approved retrospective observational study recruited 160 consecutive patients with organ-confined RCC < 7cm, (4/2012-12/2022), who underwent MWA or Robot-Assisted PN (RAPN). Outcomes included Overall (OS), Progression-Free (PFS) and Metastasis-Free (MFS) survivals, which were matched with RAPN cohorts using propensity score 1:1 matching with a logistic regression model, nearest neighbors technique and compared using Log-Rank testing.
Results:
142 patients were included in the final analysis post matching (71 MWA and 71 RAPN) with the mean tumor size being 3.1cm (± 1.4cm). At 8 years, the overall survival was 96±5% (95% CI: 91-100%), progression-free survival was 97±4% (95% CI: 93-100%) and metastasis-free survival was 97±4% (95% CI: 93-100%). Matched RAPN cohorts showed an OS of 100% (95% CI: 100-100%) PFS of 98% (95% CI: 94-100%) and MFS of 98% (95% CI: 94-100%), which were non-significantly different after log-rank testing (p-value = 0.25, 0.67 and 0.67 respectively).
Conclusion:
This long-term retrospective observational study showed comparable OS, PFS and MFS in patients with Stage I RCC treated with MWA vs RAPN.